All these clinical studies have shown that fostamatinib or R406 have generally manageable tolerability with no serious safety risks, so there is great potential for drug repurposing associated with Syk in severe asthma patients, but the target selectivity and effectiveness require further research. Here, SYK is linked to asthma.